Bayer, which currently owns a 40.8% stake in the biotech startup BlueRock Therapeutics, said it has agreed to pay $240 million for all of the company's remaining shares. Bayer could pay as much as an additional $360 million based upon progress made on several of the company's projects.
Bayer to pay $240M to get 100% of biotech startup BlueRock
Sign up for PCMA SmartBrief
Top news for PBMs
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.